sorafenib has been researched along with Invasiveness, Neoplasm in 139 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (8.63) | 29.6817 |
| 2010's | 103 (74.10) | 24.3611 |
| 2020's | 24 (17.27) | 2.80 |
| Authors | Studies |
|---|---|
| Su, D | 1 |
| Cao, W; Cui, C; Feng, W; Pi, X | 1 |
| Beppu, T; Hayashi, H; Imai, K; Isiko, T; Karashima, R; Mima, K; Miyata, T; Nitta, H; Oda, E; Okabe, H; Ozaki, N; Yamamura, K | 1 |
| Fang, W; Hou, R; Li, L; Li, Y; Liu, C; Liu, S; Liu, Z; Luo, R; Peng, X; Zhang, Y; Zuo, S | 1 |
| Gao, Y; Jiang, JD; Li, K; Li, ZR; Xue, ST; Yi, H; Zhao, LY | 1 |
| Bae, SH; Cho, EY; Jang, BK; Jang, JY; Kim, BH; Kim, DY; Kim, HJ; Kim, IH; Kim, JH; Kim, KM; Kim, YJ; Lee, BS; Lee, HW; Lee, JI; Paik, YH; Seo, YS; Sinn, DH; Suh, KS; Yim, HJ | 1 |
| Chen, Y; Ma, C; Shao, B; Zhang, F; Zhou, Y | 1 |
| Dattachoudhury, S; Jaganathan, BG; Kumar, A; Sharma, R | 1 |
| Chen, B; Chen, SY; Cheng, SH; Huang, Z; Li, YX; Liu, JX; Pan, Y; Wang, WH; Wu, F; Xu, X; Zhao, YT; Zheng, X | 1 |
| Gao, ZQ; Li, DY; Shen, PC; Tang, Z | 1 |
| Fu, J; Wang, X; Yue, Q | 1 |
| Aydin, C; Yilmaz, S | 1 |
| Hu, M; Ma, X; Yuan, Z; Zhang, J; Zhao, X | 1 |
| Li, D; Li, W; Liu, M; Yang, D; Zhang, Y; Zhao, S | 1 |
| Alvarez, ML; Angel, A; Carrillo, MC; Ceballos, MP; Comanzo, CG; Delprato, CB; Ferretti, AC; Livore, VI; Lucci, A; Mottino, AD; Quiroga, AD | 1 |
| Chang, YH; Chen, CT; Chow, LP; Huang, BS; Li, NC; Liao, LZ; Lin, LC | 1 |
| Azzaroli, F; Benevento, F; Cabibbo, G; Caturelli, E; Cucchetti, A; Di Marco, M; Farinati, F; Foschi, FG; Gasbarrini, A; Giannini, EG; Guarino, M; Marra, F; Masotto, A; Mega, A; Missale, G; Morisco, F; Nardone, G; Oliveri, F; Pontillo, G; Raimondo, G; Rapaccini, GL; Rodolfo, S; Svegliati-Baroni, G; Trevisani, F; Vidili, G; Zoli, M | 1 |
| Fu, BS; Hsu, FT; Lin, KH; Pan, PJ; Tsai, JJ; Weng, MC; Wu, CH | 1 |
| Cheng, F; He, W; Wang, J; Yao, Z; Zhang, T; Zhao, G; Zheng, B | 1 |
| Li, J; Liu, Y; Wang, Z; Wu, H; Xie, K; Zeng, Y | 1 |
| Chen, SJ; Huang, CK; Liu, F; Luo, C; Qian, H; Xiao, MC; Xie, WF; Yan, FZ; Zhang, X; Zheng, BN | 1 |
| Amendola, D; Bucci, B; Cerquetti, L; Lardo, P; Maggio, R; Petrangeli, E; Pugliese, G; Raffa, S; Stigliano, A; Torrisi, MR; Toscano, V | 1 |
| Li, X; Shi, D; Wang, F; Wang, J; Zhang, J | 1 |
| Chen, YT; Chu, XY; Xiang, D; Zhao, XY | 1 |
| Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY | 1 |
| Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lu, SN; Rau, KM; Wang, JH; Wu, IP | 1 |
| Guo, Z; Li, T; Pu, J; Wei, X; Wu, Z; Zhu, D | 1 |
| Kim, D; Ko, HS; Park, GB | 1 |
| Bruix, J; Cheng, AL; De Sanctis, Y; Llovet, J; Meinhardt, G; Nakajima, K | 1 |
| Barbera, MA; Brandi, G; Cescon, M; Cucchetti, A; De Lorenzo, S; De Pace, V; Del Gaudio, M; Frega, G; Maroni, L; Neri, F; Palloni, A; Pantaleo, MA; Pinna, AD; Ravaioli, M; Ripoli, MC | 1 |
| Cheng, H; Dong, J; Hu, F; Sun, W; Xu, J; Zhai, B | 1 |
| Adam, R; Allaham, W; Assenat, E; Aubé, C; Barraud, H; Bouattour, M; Brenot-Rossi, I; Bronowicki, JP; Castera, L; Chatellier, G; Costentin, C; Couturier, O; Dinut, A; Gerolami, R; Guiu, B; Ilonca, AD; Itti, E; Laurent, V; Lebtahi, R; Lewin, M; Luciani, A; Mathias, E; Mundler, O; Oberti, F; Pageaux, GP; Perdrisot, R; Pereira, H; Raoul, JL; Ronot, M; Samuel, D; Sarran, A; Seitz, JF; Sibert, A; Silvain, C; Tasu, JP; Vidal, V; Vilgrain, V | 1 |
| Chen, N; Chen, X; Li, X; Pan, X; Su, Z; Tan, J; Xu, M; Xu, Y; Zhang, M; Zhou, Q | 1 |
| Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Wang, Z; Xiong, Y; Xu, J; Yang, Y | 1 |
| Bertagnolli, MM; Cho, NL; Rosenberg, L; Sharma, G; Yoon, CH | 1 |
| Du, J; Zhou, XJ | 1 |
| Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nakahara, T; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S | 1 |
| Gu, FM; Guo, XG; Hou, GJ; Liu, H; Pan, ZY; Xu, QG; Yang, F; Yang, Y; Yu, J; Yuan, SX; Zhou, WP | 1 |
| Chai, ZT; Jia, QA; Ma, DN; Qin, CD; Ren, ZG; Sun, HC; Tang, ZY; Wang, CH; Zhang, N; Zhang, SZ; Zhu, XD | 1 |
| Cattan, S; Chan, SL; Cheng, AL; Daniele, B; Ebbinghaus, SW; Edeline, J; Fartoux, L; Finn, RS; Knox, J; Kudo, M; Ma, J; Ogasawara, S; Palmer, D; Sarker, D; Siegel, AB; Verset, G; Verslype, C; Vogel, A; Webber, AL; Zagonel, V; Zhu, AX | 1 |
| Aliberti, C; Benvegnù, L; Bernardi, M; Bortolini, E; Borzio, F; Borzio, M; Bucci, L; Burra, P; Cabibbo, G; Caturelli, E; Ciccarese, F; Cillo, U; Colecchia, A; Cozzolongo, R; Di Marco, M; Faggiano, C; Farinati, F; Felder, M; Fornari, F; Foschi, FG; Frigo, AC; Gasbarrini, A; Giannini, EG; Grasso, A; Marignani, M; Marra, F; Masotto, A; Morisco, F; Nardone, G; Noaro, G; Olivani, A; Pawlik, TM; Rapaccini, GL; Sacco, R; Svegliati-Baroni, G; Trevisani, F; Vicari, S; Virdone, R; Vitale, A; Zoli, M | 1 |
| Bassaganyas, L; Bruix, J; Camps, J; Chau, GY; Cillo, U; Croitoru, AE; de la Mata, M; Gane, E; Kokudo, N; Lee, HC; Llovet, JM; Lupo, L; Mazzaferro, V; Meinhardt, G; Moeini, A; Montal, R; Park, JW; Pena, C; Pinyol, R; Roayaie, S; Rodriguez-Carunchio, L; Sia, D; Solé, M; Strasser, S; Takayama, T; Thung, SN; Torrecilla, S; Verslype, C; Villanueva, A; Zhang, Z | 1 |
| Huang, W; Huang, XY; Ke, AW; Liu, D; Wang, F; Wu, J; Wu, Y; Zhang, PF; Zhang, XM | 1 |
| Chai, CY; Chiang, CM; Chiou, SS; Hsu, SH; Huang, SK; Liu, KY; Wang, LT; Wang, SN; Yokoyama, KK | 1 |
| Jiang, C; Li, XX; Wang, HY; Xu, R; Xu, XY; Yang, Y; Zheng, XFS; Zhou, YF | 1 |
| Cabibbo, G; Canale, M; Casadei Gardini, A; Cucchetti, A; De Matteis, S; Ercolani, G; Foschi, FG; Frassineti, GL; Marisi, G; Scartozzi, M; Solaini, L; Ulivi, P; Valgiusti, M | 1 |
| Allaham, W; Koulakian, H; Ronot, M; Vilgrain, V | 1 |
| Dai, J; Dai, X; Geng, F; Li, M; Liu, M | 1 |
| Fang, Q; Lu, J; Lu, Y; Wu, H; Xie, C; Xiong, Y; Yin, Z | 1 |
| Chen, M; Chen, S; Chen, Z; Feng, S; Kuang, M; Li, J; Mei, J; Peng, S; Peng, Z; Qian, G; Wang, Y; Xiao, H; Zhou, Q | 1 |
| Chai, ZT; Chen, ZH; Cheng, SQ; Cong, WM; Ding, J; Gao, YZ; Guo, WX; Lau, WY; Shi, J; Wang, K; Xie, D; Zhang, XP; Zhou, TF | 1 |
| Chen, J; Chen, T; Cui, Y; Ge, C; Li, H; Li, J; Liu, T; Song, Z; Tian, H; Yao, M; Zhao, F; Zhu, M | 1 |
| Cui, P; Huang, S; Lin, S; Ren, Y; Wang, X; Weng, G; Yao, X | 1 |
| Gong, R; Liu, LR; Nie, LH; Song, TR; Wang, JZ; Wazir, R; Wei, Q; Zhao, RN | 1 |
| Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM | 1 |
| Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M | 1 |
| Chen, L; Guo, Z; He, S; Wang, G; Wei, Y; Wu, Y; Zhang, Y; Zhou, J | 1 |
| Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY | 1 |
| Chen, C; Geng, ZM; Huanchen, S; Jha, RK; Li, B; Li, WZ; Wang, L; Zheng, JB | 1 |
| Geng, CX; Ji, YX; Lan, KT; Liu, SC; Nie, KK; Sun, L; Zhang, L; Zhang, ZC; Zhang, ZF; Zhuang, XJ; Zou, X | 1 |
| Chen, W; Chen, Y; Deng, DY; Ren, M; Shang, C; Wang, J; Xiang, Q; Zhang, H; Zhang, L | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Giannuzzi, G; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Cheung, FY; Chiang, CL; Chong, M; Jolivet, J; Kwok, C; Kwong, P; Lai, M; Lee, C; Lee, FA; Leung, KC; Siu, SW; Tung, S; Zee, BC | 1 |
| Gandhi, S; Grewal, H; Sengodan, P | 1 |
| Chi, H; Meng, Z; Wang, H; Wang, P; Xu, L; Zhu, X | 1 |
| Ji, B; Liu, K; Liu, S; Liu, Y; Wang, Y; Zhang, W | 1 |
| Harms, GS; Jaiswal, BS; Mooz, J; Oberoi-Khanuja, TK; Rajalingam, K; Seshagiri, S; Tikkanen, R; Wang, W | 1 |
| Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF | 1 |
| Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 2 |
| Luo, CL; Wu, XH; Zhao, CX | 1 |
| Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H | 1 |
| Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC | 1 |
| Liu, C; Meng, FD; Pang, Q; Qu, K; Wang, ZX; Wei, JC; Wu, QF; Zhang, LQ | 1 |
| Ardizzoni, A; Campanini, N; Dal Bello, B; Fanello, S; Maria, SE; Missale, G; Negri, FV; Poggi, G; Porta, C; Rossi, S; Salvagni, S; Tinelli, C | 1 |
| Barbara, M; Basso, M; Biolato, M; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Della Corte, C; Grieco, A; Iavarone, M; Maida, M; Vavassori, S | 1 |
| Kumar, S | 1 |
| Dong, R; Kang, M; Yang, Q; Zhang, S; Zhao, J | 1 |
| Ha, TY; Hong, HN; Hwang, S; Kim, N; Moon, KM; Ryoo, BY; Song, GW; Tak, E; Won, YJ | 1 |
| Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Yoo, BC | 1 |
| Jia, B; Jin, Z; Liu, K; Liu, S; Liu, Y; Tan, L; Zhang, W | 1 |
| Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
| Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K | 1 |
| Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L | 1 |
| Afaq, F; Athar, M; Diamond, AC; Elmets, CA; Kappes, JC; Katiyar, SK; Pal, HC; Strickland, LR | 1 |
| Chen, L; Dong, S; Gao, J; Ji, L; Kong, F; Kong, J; Pan, B; Sun, W; Zheng, L | 1 |
| Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Kawamoto, K; Marubashi, S; Mori, M; Mukai, Y; Nagano, H; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H | 1 |
| Deguchi, S; Inoue, T; Kanazawa, A; Murata, A; Nakajima, T; Nishiguchi, Y; Sakae, M; Shimizu, S; Tachimori, A; Tamamori, Y; Tsukamoto, T; Yamamoto, A; Yamamoto, S; Yamashita, Y | 1 |
| Li, X; Song, Y; Xiao, Y; Xing, Y; Xing, Z; Zhang, P; Zhao, J | 1 |
| Boone, DL; Booth, L; Chuckalovcak, J; Dent, P; Koromilas, AE; McGuire, WP; Poklepovic, A; Roberts, JL; Stringer, DK; Tavallai, M | 1 |
| Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM | 1 |
| Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF | 1 |
| Aycart, SN; Berger, Y; Edwards, MP; Heskel, M; Kim, E; Labow, DM; Sarpel, U; Spivack, JH; Sweeney, R | 1 |
| Augello, G; Bachvarov, D; Cancila, V; Candido, S; Cervello, M; Emma, MR; Gulino, A; Iovanna, JL; Libra, M; Loria, GR; McCubrey, JA; Montalto, G; Puleio, R | 1 |
| Chen, KF; Fan, LC; Hung, MH; Jiang, JK; Shiau, CW; Tai, WT; Teng, HW; Yang, SH | 1 |
| Amendola, F; Calvanese, A; Coppola, C; DI Sarno, A; Gatti, P; Giorgio, A; Giorgio, V; Matteucci, P; Merola, F; Merola, MG; Montesarchio, L; Santoro, B | 1 |
| Chen, XW; Han, JH; Hong, D; Ma, TC; Niu, M; Sun, J; Xu, K | 1 |
| Angenstein, F; Baldauf, L; Daniel, EA; Kirches, E; Mawrin, C; Pachow, D; Scholz, J; Stork, O; Tuchen, M; Wilisch-Neumann, A | 1 |
| Li, Y; Liu, L; Lu, L; Tong, X; Wang, F; Wang, X; Wu, G; Xie, J; Xue, Q; Zheng, A; Zhou, H; Zhu, X | 1 |
| Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K | 1 |
| Andrea, A; Di Silverio, F; Panebianco, V; Parente, U; Passariello, R; Sciarra, A; Von Heland, M | 1 |
| Strumberg, D | 1 |
| Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
| Bhat-Nakshatri, P; Maluccio, MA; Nakshatri, H; Saxena, R; Sheng, H; Skill, NJ; Wu, JM; Yu, M | 1 |
| Balleyguier, C; Celier, C; Escudier, B; Gautier, J; Medioni, J; Negrier, S; Oudard, S; Ravaud, A; Sablin, MP | 1 |
| Barbaro, B; Gasbarrini, A; Lauritano, EC; Novi, M; Piscaglia, AC; Pompili, M; Zocco, MA | 1 |
| Mendizabal, M; Reddy, KR | 1 |
| Kurashige, Y; Otani, A; Yoshimura, N | 1 |
| Bruix, J; de Lope, CR; Forner, A; Reig, ME | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Merle, P; Mornex, F | 1 |
| Hoshida, Y; Newell, P; Villanueva, A | 1 |
| Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D | 1 |
| Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M | 1 |
| Choi, JI; Kim, CM; Kim, HB; Kim, HK; Kim, HY; Kim, TH; Nam, BH; Park, JW | 1 |
| Hu, ML; Huang, CS; Lyu, SC | 1 |
| Anders, RA; Bai, H; Chenna, V; Fan, J; Hu, C; Khan, M; Maitra, A; Sun, HX; Sun, YF; Xu, Y; Yang, XR; Zhu, QF | 1 |
| Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA | 1 |
| Ciardiello, F; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| Gotoh, M; Kashiwagi, Y; Nakano, Y; Takeda, H; Yoshino, Y | 1 |
| Allavena, P; Mantovani, A | 1 |
| Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B | 1 |
| Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M | 1 |
| Byrne, M; Estfan, B; Kim, R | 1 |
| Lucas, LM | 1 |
| Endo, Y; Kai, K; Kawai, T; Koujima, T; Matsumoto, Y; Miyamoto, M; Nobuhisa, T; Sato, S; Toda, K; Watanabe, N; Watanabe, T; Watanabe, Y | 1 |
| Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Cabibbo, G; Campisi, G; Compilato, D; Genco, C | 1 |
| Carr, BI; Cavallini, A; Correale, M; D'Alessandro, R; Di Carlo, A; Iacovazzi, PA; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Acierno, R; Alberti, S; del Boccio, P; Giannelli, G; Maffia, M; Pieragostino, D; Sacchetta, P; Salzet, M; Simeone, P; Tinelli, A; Toto, C; Vergara, D | 1 |
| Arizumi, T; Kudo, M; Ueshima, K | 1 |
| Ding, ZB; Fan, J; Huang, XY; Ke, AW; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Xiao, YS; Yan, J; Zhang, C; Zhang, X; Zhou, J | 1 |
| Busch, S; Garbe, C; Herlyn, M; Kulms, D; Lasithiotakis, K; Maczey, E; Meier, F; Schittek, B | 1 |
| Alba, E; Medina, MA; Quesada, AR | 1 |
| Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z | 1 |
| Angelotti, U; Antonaci, S; Fransvea, E; Giannelli, G | 1 |
| Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW | 1 |
15 review(s) available for sorafenib and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2023 |
Is Macroscopic Portal Vein Tumor Thrombosis of HCC Really an Exclusion for Liver Transplantation?
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Embolization, Therapeutic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Patient Selection; Portal Vein; Preoperative Care; Radiosurgery; Sorafenib; Venous Thrombosis | 2020 |
Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Methylation; Methyltransferases; Molecular Targeted Therapy; Neoplasm Invasiveness; Nuclear Proteins; RNA, Long Noncoding; Sorafenib; Up-Regulation | 2021 |
Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers.
Topics: Biomarkers, Tumor; Carcinogenesis; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Prognosis; Sorafenib; Sunitinib; Thymus Neoplasms | 2017 |
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Leukocyte Count; Liver; Liver Neoplasms; Neoplasm Invasiveness; Prognosis; Sorafenib; Treatment Outcome | 2018 |
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Fatal Outcome; Humans; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Rare Diseases; Risk Assessment; Sorafenib; Tomography, X-Ray Computed | 2013 |
Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Ramucirumab; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Current management of hepatocellular carcinoma.
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease Progression; Hepatectomy; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Current strategy for staging and treatment: the BCLC update and future prospects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Forecasting; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Spain; Survival Analysis; Treatment Outcome | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
[Nonsurgical management of hepatocellular carcinoma].
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Radiotherapy, Conformal; Sorafenib; Yttrium Radioisotopes | 2010 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Genetic Predisposition to Disease; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Population Surveillance; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome; United States | 2010 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment | 2012 |
Extrahepatic spread of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2012 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
11 trial(s) available for sorafenib and Invasiveness, Neoplasm
| Article | Year |
|---|---|
The transcatheter arterial chemoembolization combined with targeted nanoparticle delivering sorafenib system for the treatment of microvascular invasion of hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Female; Humans; Liver; Liver Neoplasms; Male; Microvessels; Middle Aged; Nanoparticles; Neoplasm Invasiveness; Sorafenib | 2021 |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Leukocyte Count; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib | 2017 |
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Internationality; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Remission Induction; Sorafenib; Survival Rate | 2018 |
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biopsy, Needle; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Predictive Value of Tests; Prognosis; Sorafenib; Survival Analysis; Tissue Embedding; Treatment Outcome | 2019 |
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Receptor, ErbB-2; Research Design; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Sorafenib; Tomography, Spiral Computed; Venous Thrombosis | 2013 |
Sorafenib in liver function impaired advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cross-Over Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2014 |
Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Oligonucleotides; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib | 2016 |
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Brazil; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib; Time Factors; Treatment Outcome | 2012 |
113 other study(ies) available for sorafenib and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Efficacy of Lipid Nanoparticle-Loaded Sorafenib Combined with Hepatic Artery Chemoembolization in the Treatment of Primary Hepatocellular Carcinoma Complicated with Microvascular Invasion.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatic Artery; Humans; Liposomes; Liver Neoplasms; Nanoparticles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Sorafenib; Treatment Outcome | 2022 |
Positive feedback loop of FAM83A/PI3K/AKT/c-Jun induces migration, invasion and metastasis in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Feedback, Physiological; Female; Gene Silencing; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-jun; Signal Transduction; Sorafenib | 2020 |
The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Carcinoma, Hepatocellular; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Disease Progression; Drug Design; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Mutagenesis; Neoplasm Invasiveness; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley; Sorafenib | 2020 |
Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Portal Vein; Prospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Vascular Neoplasms | 2021 |
Liposomal clodronate combined with Cisplatin or Sorafenib inhibits hepatocellular carcinoma cell proliferation, migration and invasion by suppressing FOXQ1 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cisplatin; Clodronic Acid; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Neoplasm Invasiveness; RNA, Messenger; Sorafenib | 2020 |
Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; MCF-7 Cells; Mitochondria; Neoplasm Invasiveness; Sorafenib; Superoxides | 2020 |
Inhibition of EPS8L3 suppresses liver cancer progression and enhances efficacy of sorafenib treatment.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Down-Regulation; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
[Effect of sorafenib and prophylactic TACE for prevention of postoperative relapse in patients with liver cancer combined with microvascular invasion].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
Functional loss of TAGLN inhibits tumor growth and increases chemosensitivity of non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice, Inbred BALB C; Microfilament Proteins; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Sorafenib; Up-Regulation | 2020 |
KCNQ1OT1 contributes to sorafenib resistance and programmed death‑ligand‑1‑mediated immune escape via sponging miR‑506 in hepatocellular carcinoma cells.
Topics: Apoptosis; B7-H1 Antigen; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cytokines; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Immune Evasion; Liver Neoplasms; MicroRNAs; Models, Biological; Neoplasm Invasiveness; Potassium Channels, Voltage-Gated; Sorafenib; T-Lymphocytes; Tumor Microenvironment; Up-Regulation | 2020 |
Long non‑coding RNA PLK1S1 was associated with renal cell carcinoma progression by interacting with microRNA‑653 and altering C‑X‑C chemokine receptor 5 expression.
Topics: Adult; Aged; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Receptors, CXCR5; RNA, Long Noncoding; Sorafenib; Xenograft Model Antitumor Assays | 2020 |
Sirtuin 1 and 2 inhibitors enhance the inhibitory effect of sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carbazoles; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Naphthalenes; Neoplasm Invasiveness; Neoplasm Proteins; Pyrimidinones; Signal Transduction; Sirtuin 1; Sirtuin 2; Sorafenib; Spheroids, Cellular | 2021 |
Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Neoplasm Invasiveness; Phosphorylation; Phosphoserine; Prognosis; Pseudopodia; Reproducibility of Results; Signal Transduction; Sorafenib; Spheroids, Cellular; Y-Box-Binding Protein 1 | 2020 |
Pattern of macrovascular invasion in hepatocellular carcinoma.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; End Stage Liver Disease; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Italy; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Male; Mesenteric Veins; Middle Aged; Neoplasm Invasiveness; Non-alcoholic Fatty Liver Disease; Patient Acuity; Portal Vein; Prognosis; Registries; Sorafenib; Survival Rate; Tumor Burden | 2021 |
Sorafenib Induces Apoptosis and Inhibits NF-κB-mediated Anti-apoptotic and Metastatic Potential in Osteosarcoma Cells.
Topics: Apoptosis; Bone Neoplasms; Cell Line, Tumor; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Osteosarcoma; Sorafenib | 2021 |
NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.
Topics: Aged; Animals; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Mice, Inbred BALB C; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation | 2021 |
Successful management of the hepatocellular carcinoma with inferior vena cava tumor thrombus: A case report.
Topics: Carcinoma, Hepatocellular; Chemoradiotherapy, Adjuvant; Hepatectomy; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Radiosurgery; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2021 |
Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mice; Neoplasm Invasiveness; Sorafenib; Xenograft Model Antitumor Assays | 2021 |
Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Sorafenib; Tumor Cells, Cultured | 2021 |
Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Neoplasm Invasiveness; Portal Vein; Postoperative Complications; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Venous Thrombosis | 2021 |
Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Failure; Treatment Outcome | 2017 |
The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Portal Vein; Progression-Free Survival; Sorafenib; Treatment Outcome; Venous Thrombosis | 2018 |
[Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells].
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Macrophages; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
Topics: Basigin; Cell Line, Tumor; Cell Movement; Down-Regulation; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Female; Humans; Hyaluronan Receptors; Hyaluronan Synthases; Hyaluronic Acid; MAP Kinase Signaling System; Neoplasm Invasiveness; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib | 2017 |
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Administration, Metronomic; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2017 |
MicroRNA181c inhibits prostate cancer cell growth and invasion by targeting multiple ERK signaling pathway components.
Topics: Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Mitogen-Activated Protein Kinase 1; Neoplasm Invasiveness; Prostatic Neoplasms; Ribosomal Protein S6 Kinases, 90-kDa; Serum Response Factor; Sorafenib | 2018 |
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Interleukin-8A; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2018 |
Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways.
Topics: Adult; Aged; Antineoplastic Agents; Cell Proliferation; Female; Humans; Male; MAP Kinase Signaling System; Middle Aged; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2018 |
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microvessels; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2018 |
IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Epithelial-Mesenchymal Transition; Hepatectomy; Humans; Interleukin-17; Interleukin-6; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Prognosis; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Treatment Outcome | 2018 |
The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Topics: Animals; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Decitabine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; raf Kinases; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Signal Transduction; Sorafenib; Vorinostat | 2018 |
Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study.
Topics: Aged; Analysis of Variance; Carcinoma, Hepatocellular; Catheter Ablation; Clinical Decision-Making; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; Female; Hepatectomy; Humans; Infusions, Intra-Arterial; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis | 2018 |
LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma.
Topics: Carcinogenesis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; RNA, Long Noncoding; Sorafenib; Tetraspanin 24 | 2019 |
TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer.
Topics: Acetylation; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lysine Acetyltransferase 5; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Nuclear Proteins; Protein Interaction Mapping; Protein Processing, Post-Translational; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transcription Factors; Twist-Related Protein 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |
Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Oligopeptides; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Non-measurable infiltrative HCC: is post-contrast attenuation on CT a sign of tumor response?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Portal Vein; Prognosis; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Rho GTPase Activating Protein 24 (ARHGAP24) Regulates the Anti-Cancer Activity of Sorafenib Against Breast Cancer MDA-MB-231 Cells via the Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; GTPase-Activating Proteins; Humans; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2018 |
UBE2C functions as a potential oncogene by enhancing cell proliferation, migration, invasion, and drug resistance in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Invasiveness; Sorafenib; Ubiquitin-Conjugating Enzymes | 2019 |
Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver; Liver Neoplasms; Male; Microvessels; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Sorafenib; Treatment Outcome | 2019 |
Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Matched-Pair Analysis; Middle Aged; Neoplasm Invasiveness; Propensity Score; Retrospective Studies; Sorafenib | 2019 |
HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; ras Proteins; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays; Young Adult | 2019 |
The Transcription Factor Creb is Involved in Sorafenib-Inhibited Renal Cancer Cell Proliferation, Migration and Invasion.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclic AMP Response Element-Binding Protein; Dose-Response Relationship, Drug; Humans; Kidney Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Mas; Sorafenib; Time Factors | 2018 |
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Synergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Cortactin; Endocytosis; Female; Gene Knockdown Techniques; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Sorafenib inhibition of hepatic stellate cell proliferation in tumor microenvironment of hepatocellular carcinoma: a study of the sorafenib mechanisms.
Topics: Actins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatic Stellate Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2014 |
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Topics: Anilides; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blood Platelets; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2014 |
Invasive hepatocellular carcinoma with recurrent pulmonary embolism: use of AngioVac cannula thrombectomy device for mechanical aspiration.
Topics: Adult; Angiography; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Fatal Outcome; Heart Atria; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pulmonary Embolism; Sorafenib; Suction; Thrombectomy; Vena Cava, Inferior | 2014 |
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms, Experimental; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Signal Transduction; Snail Family Transcription Factors; Sorafenib; Transcription Factors | 2014 |
miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Topics: Analysis of Variance; Binding, Competitive; Blotting, Western; Cell Movement; Dimerization; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Gene Knockdown Techniques; HEK293 Cells; Humans; Indenes; MAP Kinase Kinase 1; MAP Kinase Signaling System; Models, Molecular; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrazoles; RNA, Small Interfering; Sorafenib; Time-Lapse Imaging; Tumor Cells, Cultured | 2014 |
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Metformin; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Urokinase-Type Plasminogen Activator | 2014 |
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden | 2016 |
Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitals, University; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Survival Rate; Treatment Outcome | 2014 |
Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Circulation; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cadherins; Cyclooxygenase 2; Drug Resistance, Neoplasm; Humans; Hypoxia; Kidney Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Snail Family Transcription Factors; Sorafenib; Transcription Factors; Tumor Cells, Cultured | 2015 |
Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B, Chronic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Radiography; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; Forkhead Transcription Factors; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Resistance, Neoplasm; eIF-2 Kinase; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Risk Assessment; Sorafenib; Survival Analysis; Withholding Treatment | 2015 |
Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Osteosarcoma; Phenylurea Compounds; Phosphorylation; Reactive Oxygen Species; Resting Phase, Cell Cycle; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Topics: Carcinoma, Hepatocellular; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib | 2015 |
Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Prospective Studies; Risk Factors; Sorafenib; Survival Analysis; Terminology as Topic | 2015 |
miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; PTEN Phosphohydrolase; Sorafenib | 2015 |
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1 | 2015 |
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2015 |
Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2014 |
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Movement; Cells, Cultured; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Flavonoids; Flavonols; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Melanoma; Mice, Nude; Mutation; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Metformin; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thioredoxins; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
[Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diaphragm; Hepatectomy; Humans; Liver Neoplasms; Lung; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
[A Case of Multiple HCC with Vp2 and Vv3 Invasion Controlled by Multidisciplinary Treatment Including Surgery].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cisplatin; Combined Modality Therapy; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Sorafenib | 2015 |
Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
Topics: Anoikis; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Membrane Glycoproteins; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Sorafenib | 2016 |
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Blood Vessels; Carcinoma, Hepatocellular; Contrast Media; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Osteopontin; Phenylurea Compounds; Repressor Proteins; Sequence Analysis, RNA; Signal Transduction; Sorafenib; Ultrasonography; Up-Regulation; Vascular Endothelial Growth Factor A; Vimentin; Zinc Finger E-box Binding Homeobox 2; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Focal Adhesion Kinase 1; Galectin 1; Humans; Integrin alphaVbeta3; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Morpholines; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Sorafenib; Survival Rate | 2016 |
The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
Topics: Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cell Survival; Computational Biology; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Transcription Factor RelB; Transcriptome; Young Adult | 2016 |
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Movement; Colorectal Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial-Mesenchymal Transition; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Male; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; RNA Interference; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2016 |
Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Topics: Animals; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cell Survival; Depsipeptides; Disease Models, Animal; Humans; Meningeal Neoplasms; Meningioma; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2017 |
MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib | 2017 |
Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib.
Topics: Angiogenesis Inducing Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Homeodomain Proteins; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation | 2017 |
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome; Vena Cava, Inferior | 2008 |
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; I-kappa B Proteins; Liver Neoplasms; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; Transcription Factor RelA | 2009 |
Sequential sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
Topics: Angiography; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome | 2009 |
Choroidal metastasis of renal cell carcinoma: a case report.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Choroid Neoplasms; Eye Enucleation; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2011 |
Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Norisoprenoids; Phenylurea Compounds; Phosphorylation; Pyridines; rac1 GTP-Binding Protein; rho GTP-Binding Proteins; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2012 |
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Hedgehog Proteins; Humans; Immunophenotyping; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nanocapsules; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Patched Receptors; Patched-1 Receptor; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Cell Surface; Recurrence; Signal Transduction; Sorafenib; Transcription Factors; Zinc Finger Protein GLI1 | 2012 |
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Humans; Image Processing, Computer-Assisted; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neoplasm Invasiveness; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2011 |
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Inhibitory Concentration 50; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2012 |
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2013 |
Painful leg mass.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neoplasms; Leg; Liver Neoplasms; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Pain; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Tomography, X-Ray Computed | 2012 |
[A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib | 2012 |
Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Hep G2 Cells; Humans; Janus Kinases; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Repressor Proteins; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Suppressor Proteins | 2012 |
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2013 |
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Profiling; Humans; Mesoderm; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Interaction Maps; Protein Kinases; Proteome; Proteomics; Quinazolines; Sorafenib | 2013 |
Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2012 |
αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
Topics: 14-3-3 Proteins; alpha-Crystallin B Chain; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins c-fos; Snail Family Transcription Factors; Sorafenib; Transcription Factors | 2013 |
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Humans; MAP Kinase Signaling System; Melanoma; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib; Wortmannin | 2007 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib | 2007 |
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transforming Growth Factor beta | 2008 |
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Flavonoids; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mitogen-Activated Protein Kinase Kinases; Morpholines; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sirolimus; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Wortmannin | 2008 |